Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY, Mota JM, Whiting KA, Li HA, Funt SA, Lee CH, Solit DB, Al-Ahmadie H, Milowsky MI, Balar AV, Pietzak E, Dalbagni G, Bochner BH, Ostrovnaya I, Bajorin DF, Rosenberg JE, Iyer G. Teo MY, et al. Eur Urol. 2020 Dec;78(6):907-915. doi: 10.1016/j.eururo.2020.07.018. Epub 2020 Aug 1. Eur Urol. 2020. PMID: 32753285 Free PMC article.
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Sarfaty M, Whiting K, Teo MY, Lee CH, Peters V, Durocher J, Regazzi AM, McCoy AS, Hettich G, Jungbluth AA, Al-Ahmadie H, Ostrovnaya I, Chaim J, Bajorin DF, Rosenberg JE, Iyer G, Funt SA. Sarfaty M, et al. Among authors: whiting k. Cancer Med. 2021 Feb;10(3):1074-1083. doi: 10.1002/cam4.3699. Epub 2020 Dec 31. Cancer Med. 2021. PMID: 33382520 Free PMC article. Clinical Trial.
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15].
Teo MY, Mota JM, Whiting KA, Li HA, Funt SA, Lee CH, Solit DB, Al-Ahmadie H, Milowsky MI, Balar AV, Pietzak E, Dalbagni G, Bochner BH, Ostrovnaya I, Bajorin DF, Rosenberg JE, Iyer G. Teo MY, et al. Eur Urol. 2021 May;79(5):e158-e159. doi: 10.1016/j.eururo.2021.01.031. Epub 2021 Feb 9. Eur Urol. 2021. PMID: 33579575 No abstract available.
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Funt SA, et al. Among authors: whiting k. J Clin Oncol. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. J Clin Oncol. 2022. PMID: 35089812 Free PMC article. Clinical Trial.
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
Almassi N, Whiting K, Toubaji A, Lenis AT, Jordan EJ, Won H, Regazzi AM, Chen YB, Gopalan A, Sirintrapun SJ, Fine SW, Tickoo SK, Ostrovnaya I, Pietzak EJ, Cha EK, Goh AC, Donahue TF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Teo MY, Funt SA, Rosenberg JE, Reuter VE, Bajorin DF, Solit DB, Al-Ahmadie H, Iyer G. Almassi N, et al. Among authors: whiting k. JCO Precis Oncol. 2022 Jun;6:e2100392. doi: 10.1200/PO.21.00392. JCO Precis Oncol. 2022. PMID: 35731998 Free PMC article.
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
Pietzak EJ, Whiting K, Srinivasan P, Bandlamudi C, Khurram A, Joseph V, Walasek A, Bochner E, Clinton T, Almassi N, Truong H, de Jesus Escano MR, Wiseman M, Mandelker D, Kemel Y, Zhang L, Walsh MF, Cadoo KA, Coleman JA, Al-Ahmadie H, Rosenberg JE, Iyer GV, Solit DB, Ostrovnaya I, Offit K, Robson ME, Stadler ZK, Berger MF, Bajorin DF, Carlo M, Bochner BH. Pietzak EJ, et al. Among authors: whiting k. Clin Cancer Res. 2022 Oct 3;28(19):4267-4277. doi: 10.1158/1078-0432.CCR-22-1006. Clin Cancer Res. 2022. PMID: 35833951 Free PMC article.
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
Lenis AT, Whiting K, Ravichandran V, Tallman JE, Alam SM, Chu CE, Jesus Escano M, Bochner E, Katims A, Reisz PA, Truong H, Clinton TN, Telis L, Dason S, McPherson V, Teo MY, Funt S, Aggen D, Goh AC, Donahue TF, Cha EK, Donat SM, Herr HW, Dalbagni G, Schultz N, Berger MF, Bajorin DF, Rosenberg JE, Bochner BH, Ostrovnaya I, Al-Ahmadie H, Solit DB, Iyer G, Pietzak EJ. Lenis AT, et al. Among authors: whiting k. JCO Precis Oncol. 2024 Apr;8:e2300274. doi: 10.1200/PO.23.00274. JCO Precis Oncol. 2024. PMID: 38691813 Free PMC article.
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications.
Akbulut D, Whiting K, Teo MY, Tallman JE, Ozcan GG, Basar M, Jia L, Rammal R, Chen JF, Sarungbam J, Chen YB, Gopalan A, Fine SW, Tickoo SK, Mehra R, Baine M, Bochner BH, Pietzak EJ, Bajorin DF, Rosenberg JE, Iyer G, Solit DB, Reuter VE, Rekhtman N, Ostrovnaya I, Al-Ahmadie H. Akbulut D, et al. Among authors: whiting k. Mod Pathol. 2024 Oct;37(10):100557. doi: 10.1016/j.modpat.2024.100557. Epub 2024 Jul 2. Mod Pathol. 2024. PMID: 38964503
83 results